A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

A Double-blind, Crossover, Placebo-Controlled, Multiple-dose Study to Evaluate the Effects of Vildagliptin on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00351507

Enrollment

Registered

2006-07-13

Start date

2005-05-31

Completion date

2006-02-28

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Vildagliptin, Type 2 diabetes

Brief summary

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

Interventions

DRUGVildagliptin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

35 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with type 2 diabetes for at least 6 months * Blood glucose criteria must be met * BMI in the range 22-40

Exclusion criteria

* History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes * Use of thiazolidinediones or need for insulin within 3 months prior to screening * Significant concomitant diseases or complications of diabetes * High fasting triglycerides as defined by the protocol Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Effect on gastric emptying	—

Secondary

Measure	Time frame
Effect on gastric volume	—
Effect on satiety	—
Effect on endogenous glucose appearance, glucose appearance and glucose disposal	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026